[Influenza vaccine and adjuvant].
Identifieur interne : 001246 ( Ncbi/Checkpoint ); précédent : 001245; suivant : 001247[Influenza vaccine and adjuvant].
Auteurs : Tetsuo Nakayama [Japon]Source :
- Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan [ 1347-5231 ] ; 2011.
Descripteurs français
- KwdFr :
- Adjuvants pharmaceutiques, Adulte, Antigènes (immunologie), Composés de l'aluminium, Conception de médicament, Cytokines (métabolisme), Enfant, Huile minérale, Humains, Immunité innée (immunologie), Inflammasomes (immunologie), Macrophages (immunologie), Monocytes (immunologie), Récepteurs de type Toll (immunologie), Vaccins antigrippaux (immunologie).
- MESH :
- immunologie : Antigènes, Immunité innée, Inflammasomes, Macrophages, Monocytes, Récepteurs de type Toll, Vaccins antigrippaux.
- métabolisme : Cytokines.
- Adjuvants pharmaceutiques, Adulte, Composés de l'aluminium, Conception de médicament, Enfant, Huile minérale, Humains.
English descriptors
- KwdEn :
- Adjuvants, Pharmaceutic, Adult, Aluminum Compounds, Antigens (immunology), Child, Cytokines (metabolism), Drug Design, Humans, Immunity, Innate (immunology), Inflammasomes (immunology), Influenza Vaccines (immunology), Macrophages (immunology), Mineral Oil, Monocytes (immunology), Toll-Like Receptors (immunology).
- MESH :
- chemical , immunology : Antigens, Inflammasomes, Influenza Vaccines, Toll-Like Receptors.
- chemical , metabolism : Cytokines.
- chemical : Adjuvants, Pharmaceutic, Aluminum Compounds, Mineral Oil.
- immunology : Immunity, Innate, Macrophages, Monocytes.
- Adult, Child, Drug Design, Humans.
Abstract
Adjuvant is originated from the Latin word "adjuvare" which means "help" in English to enhance the immunological responses when given together with antigens. The beginning of adjuvant was mineral oil which enhanced the immune response when it was given with inactivated Salmonella typhimurium. Aluminium salt was used to precipitate diphtheria toxoid and increased level of antibody response was demonstrated when administered with alum-precipitated antigens. Since 1930, aluminium salt has been used as DTaP (diphtheria-tetanus-acellular pertussis vaccine) adjuvant. Many candidates were tested for adjuvant activity but only aluminum salt is allowed to use for human vaccines. New adjuvant MF59, oil-in-water emulsion type, was developed for influenza vaccine for elderly (Fluad) and series of AS adjuvant are used for hepatitis B, pandemic flue, and human papiloma virus vaccines. Oil-adjuvanted influenza pandemic vaccines induced higher antibody response than alum-adjuvanted vaccine with higher incidence of adverse events, especially for local reactions. Alum-adjuvanted whole virion inactivated H5N1 vaccine was developed in Japan, and it induced relatively well immune responses in adults. When it applied for children, febrile reaction was noted in approximately 60% of the subjects, with higher antibodies. Recent investigation on innate immunity demonstrates that adjuvant activity is initiated from the stimulation on innate immunity and/or inflammasome, resulting in cytokine induction and antigen uptake by monocytes and macrophages. The probable reason for high incidence of febrile reaction should be investigated to develop a safe and effective influenza vaccine.
DOI: 10.1248/yakushi.131.1723
PubMed: 22129866
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E20
- to stream PubMed, to step Curation: 000E20
- to stream PubMed, to step Checkpoint: 000D73
- to stream Ncbi, to step Merge: 001246
- to stream Ncbi, to step Curation: 001246
Links to Exploration step
pubmed:22129866Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Influenza vaccine and adjuvant].</title>
<author><name sortKey="Nakayama, Tetsuo" sort="Nakayama, Tetsuo" uniqKey="Nakayama T" first="Tetsuo" last="Nakayama">Tetsuo Nakayama</name>
<affiliation wicri:level="3"><nlm:affiliation>Kitasato Institute for Life Sciences, Laboratory of Viral Infection I, Tokyo, Japan. tetsuo-n@lisci.kitasato-u.ac.jp</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Kitasato Institute for Life Sciences, Laboratory of Viral Infection I, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:22129866</idno>
<idno type="pmid">22129866</idno>
<idno type="doi">10.1248/yakushi.131.1723</idno>
<idno type="wicri:Area/PubMed/Corpus">000E20</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E20</idno>
<idno type="wicri:Area/PubMed/Curation">000E20</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E20</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000D73</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D73</idno>
<idno type="wicri:Area/Ncbi/Merge">001246</idno>
<idno type="wicri:Area/Ncbi/Curation">001246</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001246</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Influenza vaccine and adjuvant].</title>
<author><name sortKey="Nakayama, Tetsuo" sort="Nakayama, Tetsuo" uniqKey="Nakayama T" first="Tetsuo" last="Nakayama">Tetsuo Nakayama</name>
<affiliation wicri:level="3"><nlm:affiliation>Kitasato Institute for Life Sciences, Laboratory of Viral Infection I, Tokyo, Japan. tetsuo-n@lisci.kitasato-u.ac.jp</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Kitasato Institute for Life Sciences, Laboratory of Viral Infection I, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan</title>
<idno type="eISSN">1347-5231</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Pharmaceutic</term>
<term>Adult</term>
<term>Aluminum Compounds</term>
<term>Antigens (immunology)</term>
<term>Child</term>
<term>Cytokines (metabolism)</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Immunity, Innate (immunology)</term>
<term>Inflammasomes (immunology)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Macrophages (immunology)</term>
<term>Mineral Oil</term>
<term>Monocytes (immunology)</term>
<term>Toll-Like Receptors (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants pharmaceutiques</term>
<term>Adulte</term>
<term>Antigènes (immunologie)</term>
<term>Composés de l'aluminium</term>
<term>Conception de médicament</term>
<term>Cytokines (métabolisme)</term>
<term>Enfant</term>
<term>Huile minérale</term>
<term>Humains</term>
<term>Immunité innée (immunologie)</term>
<term>Inflammasomes (immunologie)</term>
<term>Macrophages (immunologie)</term>
<term>Monocytes (immunologie)</term>
<term>Récepteurs de type Toll (immunologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens</term>
<term>Inflammasomes</term>
<term>Influenza Vaccines</term>
<term>Toll-Like Receptors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytokines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Pharmaceutic</term>
<term>Aluminum Compounds</term>
<term>Mineral Oil</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes</term>
<term>Immunité innée</term>
<term>Inflammasomes</term>
<term>Macrophages</term>
<term>Monocytes</term>
<term>Récepteurs de type Toll</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Immunity, Innate</term>
<term>Macrophages</term>
<term>Monocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytokines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Child</term>
<term>Drug Design</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adjuvants pharmaceutiques</term>
<term>Adulte</term>
<term>Composés de l'aluminium</term>
<term>Conception de médicament</term>
<term>Enfant</term>
<term>Huile minérale</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Adjuvant is originated from the Latin word "adjuvare" which means "help" in English to enhance the immunological responses when given together with antigens. The beginning of adjuvant was mineral oil which enhanced the immune response when it was given with inactivated Salmonella typhimurium. Aluminium salt was used to precipitate diphtheria toxoid and increased level of antibody response was demonstrated when administered with alum-precipitated antigens. Since 1930, aluminium salt has been used as DTaP (diphtheria-tetanus-acellular pertussis vaccine) adjuvant. Many candidates were tested for adjuvant activity but only aluminum salt is allowed to use for human vaccines. New adjuvant MF59, oil-in-water emulsion type, was developed for influenza vaccine for elderly (Fluad) and series of AS adjuvant are used for hepatitis B, pandemic flue, and human papiloma virus vaccines. Oil-adjuvanted influenza pandemic vaccines induced higher antibody response than alum-adjuvanted vaccine with higher incidence of adverse events, especially for local reactions. Alum-adjuvanted whole virion inactivated H5N1 vaccine was developed in Japan, and it induced relatively well immune responses in adults. When it applied for children, febrile reaction was noted in approximately 60% of the subjects, with higher antibodies. Recent investigation on innate immunity demonstrates that adjuvant activity is initiated from the stimulation on innate immunity and/or inflammasome, resulting in cytokine induction and antigen uptake by monocytes and macrophages. The probable reason for high incidence of febrile reaction should be investigated to develop a safe and effective influenza vaccine.</div>
</front>
</TEI>
<affiliations><list><country><li>Japon</li>
</country>
<region><li>Région de Kantō</li>
</region>
<settlement><li>Tokyo</li>
</settlement>
</list>
<tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Nakayama, Tetsuo" sort="Nakayama, Tetsuo" uniqKey="Nakayama T" first="Tetsuo" last="Nakayama">Tetsuo Nakayama</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001246 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001246 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= Ncbi |étape= Checkpoint |type= RBID |clé= pubmed:22129866 |texte= [Influenza vaccine and adjuvant]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:22129866" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |